reset
Close search icon

Ikarovec

Company overview

Ikarovec is a biotechnology company developing differentiated gene therapy treatments for major ophthalmic diseases. The Company’s lead programs focus on one-time gene therapies for prevalent causes of vision loss that currently have limited or suboptimal treatment options.

Ikarovec’s proprietary platform builds on clinically validated therapeutic mechanisms by adding in a second synergistic component to address key disease drivers that single-pathway therapies are unable to target. Ikarovec’s pipeline targets large and growing markets, including Geographic Atrophy (an advanced form of dry age-related macular degeneration (AMD and a leading cause of irreversible blindness), wet age-related macular degeneration (wAMD), and intermediate AMD.

The Technology

Ikarovec develops next-generation, dual-pathway gene therapies designed to protect retinal cells and preserve long-term visual function. The Company’s lead technology to treat geographic atrophy (GA) targets two critical biological mechanisms:

  • Neuroprotection – preventing retinal cell death
  • Complement modulation – reducing chronic inflammation that drives disease progression

 

By addressing both cell degeneration and inflammatory damage, Ikarovec’s approach aims to deliver durable disease modification than current therapies. Preclinical studies demonstrate strong evidence of retinal cell preservation and maintained retinal function.

Expanding beyond AMD, Ikarovec is also a developing gene-agnostic therapy for Retinitis Pigmentosa (RP). This approach is designed to benefit many of >95% of RP patients with no therapy options, independent of the underlying genetic mutation, by controlling neuro-inflammation and protecting retinal function.

Company Facts

  • Headquarters: The Innovation Centre, Norwich Research Park
  • Stage: Late-stage preclinical (IND-enabling)
  • Team: Core R&D team based on-site, with US-based CEO and remote CSO. Four team members hold PhDs from the University of East Anglia (UEA)
  • Funding to Date: $11M raised across two seed rounds
  • Ownership: Private company

What next?

Ikarovec is advancing the lead asset to treat geographic atrophy, IKAR-001, with clinical trial initiation anticipated in late 2026. The Company is evolving from a research-focused organization to a clinic-ready biotech, supported by active regulatory engagement, scaled manufacturing, IND-enabling toxicology studies, and planned team expansion.

Dr Andrew Osborne said: “Norwich Research Park has fantastic facilities for emerging and growing companies. Our lab space is competitively priced, and the Park offers access to specialist equipment unaffordable to a start-up. We’re fortunate to have close links with the University of East Anglia (UEA), the Quadram Institute and clinicians at the Norfolk and Norwich University Hospital.”

Dr Emily Warner, Principal Scientist, said: “Our work also allows the sharing of expertise. We’re currently taking part in a student recruitment exercise, whereby we can directly hire University graduates. It’s amazing having all this on our doorstep.”

Norwich Research Park start-up Ikarovec sets its sight on preventing blindness – Bioscience Today

Timeline

2018

  • Ikarovec is founded, a spin-out from Quethera, a University of Cambridge gene therapy company

 

2020

  • Relocation to the Norwich Innovation Centre following the successful completion of a £2.5 million seed financing round
  • Appointment of Dr Katie Binley, who has >20 years gene therapy experience through senior roles at Oxford Biomedica, as CSO
  • Awarded a £500k Innovate UK grant to advance Ikarovec’s wet age-related macular degeneration (wetAMD) research programme
  • Company presentation to the Norwich Research Park by Dr Andy Osborne at the inaugural Enterprise Tuesday event

 

2022

  • Dr Andy Osborne delivers a career-transition seminar for Pharmacy and Bioscience students interested in moving into the biotech sector
  • Expansion of the preclinical team with the appointment of UEA PhD graduate Laura Vaux
  • Winners of the Norwich Research Park Community Quiz
  • Publication of an article in the Eastern Daily Press (EDP) outlining Ikarovec’s company vision and approach to patient engagement

 

2023

  • Hosting of a PIPS (Professional Internship Placement Scheme) student, supporting early-career development
  • Dr Andy Osborne featured on BBC Radio Norfolk, discussing Ikarovec’s work and regional biotech innovation

 

2024

  • Expansion of seed funding to £8 million, supporting company growth and programme advancement
  • Acquisition of additional office space in Enterprise House, enabling expansion of the team to six members
  • Andy Osborne serves as a panellist at the Norwich Research Park Enterprise Tuesday Conference
  • Launch of an AAV formulation consortium in collaboration with the Cell and Gene Therapy Catapult, UCL, and Croda
  • Dr Emily Warner delivers a local careers update to UEA PhD students

 

2025

  • Appointment of Thomas Ciulla, MD, MBA, a recognised leader in ophthalmology drug development, as President and CEO
  • Announcement of a World Class Global Scientific Advisory Board
  • Positive regulatory feedback on developmental plans via an FDA INTERACT meeting
  • Manufacturing CDMO scale-up is supported by in-house vector analytics and the appointment of UEA PhD scientist Dr Chris Benwell
  • Dr Laura Vaux presents her career journey, contributing to outreach and mentoring initiatives

 

2026